Effects of ¹³¹I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer.

IF 3.6 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-01-15 eCollection Date: 2025-01-01 DOI:10.62347/THJB4749

Li-Guo Yang, Zhi-Gang Yang, Jun Zhang, Yi-Li Fu

{"title":"Effects of 131I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer.","authors":"Li-Guo Yang, Zhi-Gang Yang, Jun Zhang, Yi-Li Fu","doi":"10.62347/THJB4749","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to evaluate the changes in the expression levels of METTL3 and METTL14 in patients with differentiated thyroid cancer (DTC) and their association with thyroid function indicators, as well as to explore the potential value of these genes in predicting the risk of DTC recurrence.Methods: This cohort study included 189 DTC patients treated at Shidong Hospital between April 2016 and February 2021. Patients were divided into an experimental group, which received combined radioactive iodine (131I) therapy and thyroid-stimulating hormone (TSH) suppression therapy (n = 119), and a control group, which received only TSH suppression therapy (n = 70). Messenger RNA (mRNA) expression levels of METTL3 and METTL14 in patients' serum were measured before and six months after treatment using quantitative real-time polymerase chain reaction (qRT-PCR). Thyroid function indicators, including free triiodothyronine (FT3), free thyroxine (FT4), TSH, and thyroglobulin (Tg), were assessed using electrochemiluminescence immunoassay. Disease-free survival (DFS) was analyzed using Cox regression analysis, and data visualization was performed with the ggplot2 package in R.Results: Both METTL3 and METTL14 expression levels significantly decreased after treatment in both the experimental and control groups (P < 0.001). Regarding thyroid function indicators, FT3 and FT4 levels significantly increased, while TSH and Tg levels significantly decreased post-treatment (P < 0.001). Lower post-treatment expression levels of METTL3 and METTL14 were significantly associated with a higher risk of recurrence. Cox regression analysis further indicated that post-treatment METTL3, METTL14, TSH, and Tg levels were independent predictors of DFS (P < 0.05).Conclusion: Low expression levels of METTL3 and METTL14 are closely associated with malignant progression and an increased risk of recurrence in DTC. Patients receiving combined 131I and TSH suppression therapy demonstrated longer DFS. These findings suggest that METTL3 and METTL14 could serve as potential biomarkers for prognosis evaluation in DTC patients.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 1","pages":"42-58"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815380/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/THJB4749","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to evaluate the changes in the expression levels of METTL3 and METTL14 in patients with differentiated thyroid cancer (DTC) and their association with thyroid function indicators, as well as to explore the potential value of these genes in predicting the risk of DTC recurrence.

Methods: This cohort study included 189 DTC patients treated at Shidong Hospital between April 2016 and February 2021. Patients were divided into an experimental group, which received combined radioactive iodine (¹³¹I) therapy and thyroid-stimulating hormone (TSH) suppression therapy (n = 119), and a control group, which received only TSH suppression therapy (n = 70). Messenger RNA (mRNA) expression levels of METTL3 and METTL14 in patients' serum were measured before and six months after treatment using quantitative real-time polymerase chain reaction (qRT-PCR). Thyroid function indicators, including free triiodothyronine (FT3), free thyroxine (FT4), TSH, and thyroglobulin (Tg), were assessed using electrochemiluminescence immunoassay. Disease-free survival (DFS) was analyzed using Cox regression analysis, and data visualization was performed with the ggplot2 package in R.

Results: Both METTL3 and METTL14 expression levels significantly decreased after treatment in both the experimental and control groups (P < 0.001). Regarding thyroid function indicators, FT3 and FT4 levels significantly increased, while TSH and Tg levels significantly decreased post-treatment (P < 0.001). Lower post-treatment expression levels of METTL3 and METTL14 were significantly associated with a higher risk of recurrence. Cox regression analysis further indicated that post-treatment METTL3, METTL14, TSH, and Tg levels were independent predictors of DFS (P < 0.05).

Conclusion: Low expression levels of METTL3 and METTL14 are closely associated with malignant progression and an increased risk of recurrence in DTC. Patients receiving combined ¹³¹I and TSH suppression therapy demonstrated longer DFS. These findings suggest that METTL3 and METTL14 could serve as potential biomarkers for prognosis evaluation in DTC patients.

查看原文本刊更多论文

131I和TSH抑制治疗对甲状腺癌METTL3、METTL14水平及复发的影响

目的：本研究旨在评价分化型甲状腺癌（DTC）患者METTL3和METTL14表达水平的变化及其与甲状腺功能指标的相关性，并探讨这些基因在预测DTC复发风险中的潜在价值。方法：本队列研究纳入2016年4月至2021年2月在石东医院就诊的189例DTC患者。将患者分为实验组（119例）和对照组（70例），实验组采用放射性碘（131I）联合促甲状腺激素（TSH）抑制治疗，对照组仅采用TSH抑制治疗。采用实时荧光定量聚合酶链反应（qRT-PCR）检测治疗前和治疗后6个月患者血清中METTL3和METTL14 mRNA表达水平。采用电化学发光免疫分析法评估甲状腺功能指标，包括游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、TSH和甲状腺球蛋白（Tg）。采用Cox回归分析无病生存期（DFS），并采用r . ggplot2软件包进行数据可视化。结果：实验组和对照组治疗后METTL3和METTL14表达水平均显著降低（P < 0.001）。甲状腺功能指标治疗后FT3、FT4水平显著升高，TSH、Tg水平显著降低（P < 0.001）。治疗后较低的METTL3和METTL14表达水平与较高的复发风险显著相关。Cox回归分析进一步表明，治疗后METTL3、METTL14、TSH、Tg水平是DFS的独立预测因子（P < 0.05）。结论：低表达的METTL3和METTL14与DTC的恶性进展和复发风险增加密切相关。接受131I和TSH联合抑制治疗的患者表现出更长的DFS。这些发现提示METTL3和METTL14可以作为DTC患者预后评估的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.